INCY

SEC source: 0002039219-26-000010 · wk-form4_1791230516.xml · nonDerivative · entry 1

Heeson Lee · CIK 0002039219 · EVP, Head of Incyte Intl

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,578

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 26,884 shares of common stock issuable pursuant to previously reported RSUs that have not vested.

SEC source: 0001177917-26-000014 · wk-form4_1790971323.xml · nonDerivative · entry 1

HARRIGAN EDMUND · CIK 0001177917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,225

F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.

F2 · balance_after: This includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001409601-26-000015 · wk-form4_1790971354.xml · nonDerivative · entry 1

Clancy Paul J · CIK 0001409601 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,838

F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.

F2 · balance_after: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001193125-26-412653 · ownership.xml · nonDerivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 28,206,082

F1 · shares: Includes 322 shares of common stock ("Common Stock") of Incyte Corporation (the "Issuer") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of quarterly director retainer fees of $40,500. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds or for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: Includes beneficial ownership of 15,505 shares of Common Stock previously issued to Julian C. Baker pursuant to the Stock Incentive Plan in lieu of director retainer fees, 14,722 shares of Common Stock received previously from vested restricted stock units payable solely in Common Stock (each an "RSU"), 1,642 shares of Common Stock underlying unvested RSUs and 245,000 shares of Common Stock received previously from the exercise of 245,000 non-qualified stock options exercisable solely into Common Stock ("Stock Options") that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the Funds are deemed to own a portion.

F6 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board, and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options, Common Stock issued upon exercise of Stock Options, RSUs and Common Stock received upon vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F7 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Common Stock received in lieu of director retainer fees, Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F8 · ownership.nature: The acquisitions of RSUs reported on this form represent a single grant of 322 RSUs on Table I. The 322 RSUs are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F9 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0001193125-26-412653 · ownership.xml · nonDerivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,835,403

F1 · shares: Includes 322 shares of common stock ("Common Stock") of Incyte Corporation (the "Issuer") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of quarterly director retainer fees of $40,500. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F2 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds or for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: Includes beneficial ownership of 15,505 shares of Common Stock previously issued to Julian C. Baker pursuant to the Stock Incentive Plan in lieu of director retainer fees, 14,722 shares of Common Stock received previously from vested restricted stock units payable solely in Common Stock (each an "RSU"), 1,642 shares of Common Stock underlying unvested RSUs and 245,000 shares of Common Stock received previously from the exercise of 245,000 non-qualified stock options exercisable solely into Common Stock ("Stock Options") that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the Funds are deemed to own a portion.

F6 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board, and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options, Common Stock issued upon exercise of Stock Options, RSUs and Common Stock received upon vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F7 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Common Stock received in lieu of director retainer fees, Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F8 · ownership.nature: The acquisitions of RSUs reported on this form represent a single grant of 322 RSUs on Table I. The 322 RSUs are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

SEC source: 0002085970-26-000007 · wk-form4_1790280388.xml · nonDerivative · entry 1

Gardner David H · CIK 0002085970 · EVP, Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,904

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 14,467 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001205703-26-000030 · wk-form4_1789675474.xml · derivative · entry 10

CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,466

Underlying: Common Stock · 9,233 shares

Expires 2035-01-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years.

SEC source: 0001205703-26-000030 · wk-form4_1789675474.xml · derivative · entry 9

CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,356

Underlying: Common Stock · 6,477 shares

Expires 2034-07-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

SEC source: 0001205703-26-000030 · wk-form4_1789675474.xml · derivative · entry 8

CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,551

Underlying: Common Stock · 4,551 shares

Expires 2034-01-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Beginning January 18, 2024, options become exercisable in 37 installments, with the first 25% vesting on July 14, 2024 and the remainder vesting monthly over three years.

SEC source: 0001205703-26-000030 · wk-form4_1789675474.xml · derivative · entry 7

CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,225

Underlying: Common Stock · 2,957 shares

Expires 2033-07-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The July 14, 2023 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

SEC source: 0001205703-26-000030 · wk-form4_1789675474.xml · nonDerivative · entry 6

CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 183,200

F1 · balance_after: This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

SEC source: 0001205703-26-000030 · wk-form4_1789675474.xml · nonDerivative · entry 5

CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 197,185

SEC source: 0001205703-26-000030 · wk-form4_1789675474.xml · nonDerivative · entry 4

CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 206,418

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001205703-26-000030 · wk-form4_1789675474.xml · nonDerivative · entry 3

CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 197,185

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001205703-26-000030 · wk-form4_1789675474.xml · nonDerivative · entry 2

CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 190,708

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001205703-26-000030 · wk-form4_1789675474.xml · nonDerivative · entry 1

CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 186,157

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0002083591-26-000007 · wk-form4_1787861247.xml · nonDerivative · entry 1

Basi Ramitpal K · CIK 0002083591 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,993

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 9,871 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001205703-26-000028 · wk-form4_1787260512.xml · nonDerivative · entry 1

CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 183,200

F1 · balance_after: This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

SEC source: 0001205703-26-000027 · wk-form4_1786737658.xml · nonDerivative · entry 1

CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 194,001

F1 · balance_after: This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

SEC source: 0001205703-26-000025 · wk-form4_1786132939.xml · nonDerivative · entry 1

CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 204,804

F1 · balance_after: This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

SEC source: 0002079962-26-000015 · wk-form4_1786132914.xml · derivative · entry 3

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,207 shares

Expires 2030-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: As of August 5th, 2026, the award is fully vested and exercisable

SEC source: 0002079962-26-000015 · wk-form4_1786132914.xml · nonDerivative · entry 2

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 61,441

F1 · balance_after: This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested.

SEC source: 0002079962-26-000015 · wk-form4_1786132914.xml · nonDerivative · entry 1

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 63,648

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · derivative · entry 44

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,055 shares

Expires 2027-11-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: As of July 31st, 2026, the award is fully vested and exercisable.

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 28

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 61,441

F1 · balance_after: This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested.

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 27

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 67,496

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001205703-26-000023 · wk-form4_1785873861.xml · nonDerivative · entry 1

CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 215,444

F1 · balance_after: This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · derivative · entry 43

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,055

Underlying: Common Stock · 326 shares

Expires 2027-11-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: As of July 31st, 2026, the award is fully vested and exercisable.

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · derivative · entry 42

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,207

Underlying: Common Stock · 85 shares

Expires 2030-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: As of July 31st, 2026, the award is fully vested and exercisable.

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · derivative · entry 41

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,293 shares

Expires 2031-01-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: As of July 31st, 2026, the award is fully vested and exercisable.

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · derivative · entry 40

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,642 shares

Expires 2029-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: As of July 31st, 2026, the award is fully vested and exercisable.

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · derivative · entry 39

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,623 shares

Expires 2031-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: As of July 31st, 2026, the award is fully vested and exercisable.

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · derivative · entry 38

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 202

Underlying: Common Stock · 3,023 shares

Expires 2033-01-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: As of July 31st, 2026, the award is fully vested and exercisable.

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · derivative · entry 37

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,643 shares

Expires 2030-01-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: As of July 31st, 2026, the award is fully vested and exercisable.

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · derivative · entry 36

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 191

Underlying: Common Stock · 2,864 shares

Expires 2032-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: As of July 31st, 2026, the award is fully vested and exercisable.

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · derivative · entry 35

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,623 shares

Expires 2032-01-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: As of July 31st, 2026, the award is fully vested and exercisable.

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · derivative · entry 34

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,459 shares

Expires 2029-01-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: As of July 31st, 2026, the award is fully vested and exercisable.

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · derivative · entry 33

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,665

Underlying: Common Stock · 2,072 shares

Expires 2035-01-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: Options granted on January 17, 2025 and will vest monthly through July 15, 2028

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · derivative · entry 32

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,148 shares

Expires 2028-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: As of July 31st, 2026, the award is fully vested and exercisable.

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · derivative · entry 31

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,233

Underlying: Common Stock · 2,709 shares

Expires 2033-07-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Options granted on July 14, 2023 and will vest monthly through July 14, 2027

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · derivative · entry 30

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,938

Underlying: Common Stock · 2,284 shares

Expires 2034-07-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Options granted on July 15, 2024 and will vest monthly through July 15, 2028

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · derivative · entry 29

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,328

Underlying: Common Stock · 2,918 shares

Expires 2034-01-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Options granted on January 18, 2024 and will vest monthly through July 14, 2027

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 26

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 61,441

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 25

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 63,734

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 24

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 64,060

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 23

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 64,145

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 22

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 65,787

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 21

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 67,430

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 20

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 70,294

SEC source: 0002079962-26-000013 · wk-form4_1785873838.xml · nonDerivative · entry 19

Mayes Patrick A · CIK 0002079962 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 74,989